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Background: To achieve high-level production of non-native isoprenoid products, it requires the metabolic flux to be
diverted from the production of sterols to the heterologous metabolic reactions. However, there are limited tools for
restricting metabolic flux towards ergosterol synthesis. In the present study, we explored dynamic control of ERG9
expression using different ergosterol-responsive promoters to improve the production of non-native isoprenoids.
Results: Several ergosterol-responsive promoters were identified using quantitative real-time PCR (qRT-PCR) analysis in
an engineered strain with relatively high mevalonate pathway activity. We found mRNA levels for ERG11, ERG2 and ERG3
expression were significantly lower in the engineered strain over the reference strain BY4742, indicating these genes are
transcriptionally down-regulated when ergosterol is in excess. Further replacement of the native ERG9 promoter with
these ergosterol-responsive promoters revealed that all engineered strains improved amorpha-4,11-diene by 2 ~ 5-fold
over the reference strain with ERG9 under its native promoter. The best engineered strain with ERG9 under the control of
PERG1 produced amorpha-4,11-diene to a titer around 350 mg/L after 96 h cultivation in shake-flasks.
Conclusions: We envision dynamic control at the branching step using feedback regulation at transcriptional level
could serve as a generalized approach for redirecting the metabolic flux towards product-of-interest.
Keywords: Mevalonate pathway, Dynamic control, ERG9, Ergosterol-responsive promoter, Isoprenoids, Saccharomyces
cerevisiaeBackground
Microbial production of natural products in genetically
tractable microbes has gained tremendous interest in the
recent years. In order to produce these molecules at
industrial levels, pathway genes involved in the synthesis
of these molecules must be expressed at appropriately
balanced levels, to avoid the accumulation of toxic inter-
mediates or bottlenecks that result in growth inhibition
or suboptimal yields [1-3]. Moreover, it often requires the
metabolic flux towards side pathways to be minimized or
completely eliminated [4-8]. For example, high-level
production of non-native isoprenoid products requires the
metabolic flux to be diverted from the production of* Correspondence: cheyuan@nus.edu.sg; cheching@nus.edu.sg
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Down-regulation of ERG9 gene which encodes squalene
synthase (the first committed step after farnesyl diphosphate
in ergosterol biosynthesis), using the methionine-repressible
MET3 promoter or copper-repressible CTR3 promoter,
increased amorpha-4,11-diene production an additional
2-fold [9,10]. Other approaches such as harnessing
weak promoter for controlling ERG9 expression and
utilizing HXT1 promoter to couple ERG9 expression
with glucose concentration also showed promising
results [4,11].
As ergosterol fulfills several essential functions and
each requires optimal sterol concentrations, synthesis of
sterols in yeast is tightly regulated. In budding yeast, it
requires thirteen-enzymatic steps to synthesize ergosterol
from farnesyl diphosphate – a precursor from the mevalo-
nate pathway (Figure 1). Previously, ERG9 expression in
yeast was reported to be positively and negatively
regulated by diverse factors such as the heme activatortral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic diagram of ergosterol-responsive promoters for controlling the metabolic flux towards erogosterol biosynthesis
pathway. Genes from the mevalonate pathway in S. cerevisiae are shown in blue; heterologous expression of ADS gene is shown in green; and
genes from ergosterol biosynthesis pathway are shown in red. The ERG9 expression is put under the control of ergosterol-responsive promoter
(PERG) to achieve dynamic control of squalene synthase availability in response to intracellular ergosterol levels. The pathway intermediates IPP,
DMAPP and FPP are defined as isopentenyl pyrophosphate, dimethylallyl pyrophosphate and farnesyl diphosphate, respectively.
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lipid transcription factor complex INO2/4 [12,13]. Sterol
biosynthetic mutations at ERG3, ERG7 and ERG24 also in-
creased ERG9 expression level. However, naturally oc-
curring cognate regulator for ERG9 expression will
rarely suffice to regulate an engineered pathway with
higher metabolic flux. This leads us to search for
other ergosterol-responsive promoters from ergosterol
biosynthesis pathway (Table 1) for a better and tighter
control of ERG9 expression, with further improved
production of non-native isoprenoids. Previous inves-
tigations revealed that genes involved in ergosterol
biosynthesis pathway such as ERG1, ERG11, ERG2
and ERG3 were transcriptionally up-regulated when
yeast cells are treated with inhibitors to restrict metabolic
flux towards ergosterol biosynthesis [14-16]. Therefore,
these ergosterol-responsive promoters can be interesting
candidates for the dynamic regulation of ERG9 expression
in budding yeast.Here, we investigated mRNA levels of ERG1, ERG11,
ERG2 and ERG3 in an engineered yeast with relatively
high mevalonate pathway activity [3]. Among these
candidates, we found ERG11, ERG2 and ERG3 were
transcriptionally down-regulated in our engineered
strain when compared to the reference strain of
BY4742, whereas mRNA level of ERG1 gene in both
strains remained relatively low. When the engineered
strains with ERG9 under the control of different
ergosterol-responsive promoters were examined for
the production of amorpha-4,11-diene (Figure 1), strains
showed 2 ~ 5-fold higher levels of amorpha-4,11-diene
than the reference strain. Among them, PERG1 showed the
best result for improving amorpha-4,11-diene production
yielding a final titer around 350 mg/L after 96 h cultiva-
tion in 250 mL shake-flasks. We envision dynamic control
using side-product regulated systems could serve as an
attractive strategy for redirecting metabolic flux towards
product-of-interest. The methodology described here
Table 1 List of genes involved in the mevalonate and
ergosterol biosynthesis pathways
Gene Discription
The mevalonate biosynthesis pathway
ERG10 Acetyl-CoA C-acetyltransferase (EC:2.3.1.9)
ERG13 Hydroxymethylglutaryl-CoA synthase (EC:2.3.3.10)
HMG1/2 Hydroxymethylglutaryl-CoA reductase (EC:1.1.1.34)
ERG12 Mevalonate kinase (EC:2.7.1.36)
ERG8 Phosphomevalonate kinase (EC:2.7.4.2)
ERG19 Diphosphomevalonate decarboxylase (EC:4.1.1.33)
IDI1 Isopentenyl-diphosphate delta-isomerase (EC:5.3.3.2)
ERG20 Bifunctional (2E,6E)-farnesyl diphosphate synthase/
dimethylallyltranstransferase (EC:2.5.1.10)
The ergosterol biosynthesis pathway
ERG9 Squalene synthase (EC:2.5.1.21)
ERG1 Squalene monooxygenase (EC:1.14.13.132)
ERG7 Lanosterol synthase (EC:5.4.99.7)
ERG11 Lanosterol demethylase (EC:1.14.13.70)
ERG24 C-14 sterol reductase (EC:1.3.1.70)
ERG25 Methylsterol monooxygenase (EC:1.14.13.72)
ERG26 Sterol-4-alpha-carboxylate 3-dehydrogenase,
decarboxylating (EC:1.1.1.170)
ERG27 3-keto-steroid reductase (EC:1.1.1.270)
ERG6 Sterol 24-C-methyltransferase (EC:2.1.1.41)
ERG2 C-8 sterol isomerase (EC:5.3.3.5)
ERG3 C-5 sterol desaturase (EC:1.3.3.-)
ERG5 C-22 sterol desaturase (EC:1.14.-.-)
ERG4 C24(28) sterol reductase (EC:1.3.1.71)
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pathways.
Results
Characterization of ERG1, ERG11, ERG2 and ERG3
expression levels in the engineered strains with high
mevalonate pathway activity
As ergosterol fulfills several essential functions that
require optimal sterol concentrations, synthesis of sterols
in yeast must be tightly regulated. For example, squalene
epoxidase (encoded by ERG1) is an essential enzyme in the
ergosterol-biosynthesis pathway and catalyzes the squalene
epoxidation step. Inhibition of ergosterol biosynthesis
with the antifungal drug terbinafine at squalene epoxidase
step can trigger increased level of ERG1 expression in a
concentration-dependent manner to a maximum of
sevenfold [15]. Inhibition of a later step in the ergosterol
biosynthetic pathway by ketoconazol, an inhibitor of the
lanosterol-14α-demethylase (encoded by ERG11), also
induces the expression of ERG1, indicating that ERG1
expression is positively regulated by diminishedintracellular ergosterol levels. Similarly, various other er-
gosterol biosynthetic pathway genes such as ERG11
[17,18], ERG2 [16] and ERG3 [14] are transcriptionally
up-regulated when ergosterol biosynthesis is inhibited
using different drugs. Therefore, it is likely that ergosterol-
responsive promoters – by definition – will respond
to excessive amounts of intracellular ergosterol and
trigger the down-regulation of corresponding genes
accordingly.
In the present study, we decided to investigate whether
the abovementioned genes, namely, ERG1, ERG11, ERG2
and ERG3, are transcriptionally downregulated in the
engineered strain with relatively high mevalonate pathway
activity. Previously, our group has successfully engineered
yeast strains with significant improvement of mevalo-
nate pathway activity for high-level production of
amorpha-4,11-diene. Notably, we found that strain
M4-2nd without ADS gene showed extremely slow growth
profile as compared to BY4742 when cultivated in galactose
medium (data not shown) suggesting that the accumulation
of intermediates such as DMAPP, IPP and FPP might be
toxic to the yeast cells, as they are in E. coli [19]. Therefore,
strain M4-2nd expressing ADS gene was used for mRNA
extraction in the induction medium. When comparing the
mRNA abundance of ERG1, ERG11, ERG2 and ERG3 in
the engineered strain M4-2nd over the reference strain
BY4742, we found ERG11, ERG2 and ERG3 did show a
sharp decrease of mRNA levels in the engineered strain
M4-2nd (Figure 2). Intriguingly, there was no obvious
change for ERG1 expression levels between the reference
strain and the engineered strain (Figure 2), and the mRNA
abundances of ERG1 in both strains were relatively low,
which may also explain the accumulation of large amount
of squalene in an engineered yeast with deregulated expres-
sion of HMG-CoA reductase, whereas the sterol contents
showed only small changes [18].
Amorpha-4,11-diene production in engineered strains with
ERG9 under the control of different ergosterol-responsive
promoters
As different transcripts may have varying half-lives,
the relative strengths of abovementioned ergosterol-
responsive promoters are not reflected by qRT-PCR
analysis as shown in Figure 2. The use of reporter genes
such as lacZ under different ergosterol-responsive pro-
moters may help determine the promoter strengths, but it
will be too cumbersome to systematically evaluate the rela-
tive promoter strengths during different growth phases.
Therefore, upon successful demonstration of transcriptional
down-regulation of ergosterol biosynthesis genes in the
engineered strain with high mevalonate pathway activity,
we sought to directly test our engineered strains with ERG9
under the control of different ergosterol-responsive
promoters for amorpha-4,11-diene production [20].
Figure 2 qRT-PCR analysis of ERG1, ERG11, ERG2 and ERG3 in an engineered strain with high mevalonate pathway activity over the
reference strain BY4742. Two cultures of each strain, BY4742 (Control) and M4-2nd, were inoculated in SC media at initial OD600 of 0.05 and
harvested at early-log phase for qRT-PCR analysis. The results are presented as the relative abundances of ERG1, ERG11, ERG2 and ERG3 in each
strain with respect to ACT1. Values represented the average and standard deviation of three independent experiments.
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under different ergosterol-responsive promoters were trans-
formed with pRS415ADS to evaluate the effect of dynamic
control of ERG9 expression on amorpha-4,11-diene
production. The resulting strains were designated as
M4-D1, M4-D2, M4-D3, and M4-D4 with the ERG1,
ERG2, ERG3, and ERG11 promoters to drive ERG9
expression, respectively (Table 2). Interestingly, all
engineered strains with ERG9 under different ergosterol-
responsive promoters improved the amorpha-4,11-diene
titer substantially, with up to a 5-fold improvement over
the reference strain, which contains ERG9 under its native
promoter (Figure 3B). Among these strains, strain M4-D1
showed the best result at 5-fold improvement and pro-
duced amorpha-4,11-diene to a final titer around 350 mg/L
after 96 h cultivation in shake flasks, suggesting that ERG9
under the control of PERG1 most efficiently restricted meta-
bolic flux towards ergosterol biosynthesis. Moreover, there
was an inverse correlation of amorpha-4,11-diene levels to
growth rate during the early exponential phase (Figure 3A).
As these ergosterol-responsive promoters can respond to
the diminished level of ergosterol and compensate with
elevated transcription levels [14,15,17], the perturbation of
growth rate might be caused by the accumulation of toxic
intermediates, as seen in E. coli [19]. To further confirm
that the improved amorpha-4,11-diene titer in strains
M4-D1 ~ D4 was attributed to the regulation of ERG9
expression, we next sought to systematically compare
the mRNA abundance of ERG9 in all engineered strains.
As can be seen from Figure 4, qRT-PCR analysis revealedthat mRNA levels of ERG9 in strains M4-D1 ~D4 were
significantly lower when compared to the reference strain
M4-2nd, indicating that the improvement of amorpha-
4,11-dien levels was caused by ERG9 restriction using
ergosterol-repsonsive promoters. Collectively, our findings
suggested dynamic control of ERG9 expression using
ergosterol-responsive promoters could be an alternative
strategy for improving isoprenoid productions. Future
work will be focusing on optimizing the dynamic-sensor
device and FPP consumption module to allow the
consumption of intermediates at the appropriate rates
for optimal pathway activities.
Discussion
Dynamic regulation would allow an organism to adapt
its metabolic flux to changes within the host or in its
environment [21], which would allow the delivery of
intermediates at the appropriate levels and rates for
optimal pathway activities. In one of the pioneering
examples of dynamic regulation system, acetyl phosphate
was used as an indirect indicator for excess amount of
glucolytic flux to regulate the heterologous lycopene
biosynthesis pathway [22]. Recently, Zhang et al. demon-
strated that dynamic regulation using FadR-based sensing
device in E. coli could improve the FAEE production
by 3-fold to 28% of theoretical maximum and also
substantially improve the stability of biodiesel-producing
strains [23]. In a more recent effort, Dahl et al. exploited
the stress-response promoter system to dynamically control
the mevalonate biosynthesis pathway in E. coli and the
Table 2 List of plasmids and strains used in the present study
Name Description References
Plasmid name
pUC18 Plasmid for cloning in E. coli Invitrogen
pUG72 Plasmid harboring URA3 selection marker [30]
pSH68 Plasmid harboring Cre gene under the control of PGAL1 [30]
pRS425ADS pRS425::PGAL1-ADS-TCYC1 [9]
pRS415ADS pSH68 derivative with pRS415::PGAL1-ADS-TCYC1 This study
pURA3-Blank pUC18 derivative containing URA3 selection marker from pUG72 This study
pURA3-ERG1p pURA3-Blank derivative with insertion of promoter region from ERG1 gene This study
pURA3-ERG11p pURA3-Blank derivative with insertion of promoter region from ERG11 gene This study
pURA3-ERG2p pURA3-Blank derivative with insertion of promoter region from ERG2 gene This study
pURA3-ERG3p pURA3-Blank derivative with insertion of promoter region from ERG3 gene This study
Strain name
M4-2nd BY4742 derivative with the relatively high mevalonate pathway activity [3]
M4-D1 M4-2nd with ERG9 under the control of PERG1 This study
M4-D2 M4-2nd with ERG9 under the control of PERG11 This study
M4-D3 M4-2nd with ERG9 under the control of PERG2 This study
M4-D4 M4-2nd with ERG9 under the control of PERG3 This study
M4-2nd-L Strain M4-2nd harboring plasmid pRS415ADS This study
M4-D1-L Strain M4-D1 harboring plasmid pRS415ADS This study
M4-D2-L Strain M4-D2 harboring plasmid pRS415ADS This study
M4-D3-L Strain M4-D3 harboring plasmid pRS415ADS This study
M4-D4-L Strain M4-D4 harboring plasmid pRS415ADS This study
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4,11-diene production compared to either a constitu-
tive expression system or an IPTG inducible system
[24]. Nature has provided abundant ligand-responsive
transcription factors, whose DNA-binding activities
are regulated by various types of molecules, including
nucleic acids, carbohydrates, lipids, amino acids and
many secondary metabolites [23]. For example, tyrR
transcriptional factor from E. coli was reported to play an
important role for regulating L-tyrosine biosynthesis path-
way [25] and those tyrR-mediated tyrosine-responsive
promoters may be used for dynamically controlling the
side-pathway expressions and improving the product titer
of tyrosine-derived compounds such as alkaloids.
High-level production of product-of-interest in microbial
hosts also requires the metabolic flux towards competing
pathways to be minimized or completely eliminated if it is
not essential for the cells to survive [4-8]. However, many
competing pathways inside the cell are producing
compounds that are essential to support cell growth.
For example, isoprenoid biosynthesis pathway is not
only essential for ergosterol production to maintain
proper membrane structure, but also for heme A and
ubiquinone biosynthesis. Deletion of ERG9 gene to block
metabolic flux towards biosynthesis of these essentialcomponents would result in inviable strains. Currently,
researchers have explored the methionine-repressible
MET3 promoter or copper-repressible CTR3 promoter for
restricting ERG9 expression to divert metabolic flux from
ergosterol biosynthesis to non-native isoprenoid pro-
duction, which improved amorpha-4,11-diene production
an additional 2-fold [9,10]. Other approaches such as
harnessing a weak CYC1 promoter for controlling ERG9
expression or using a HXT1 promoter to couple ERG9
expression with glucose concentration also showed exciting
results [4,11]. Here, we demonstrated that dynamic control
of ERG9 expression using ergosterol feedback regulation
mechanism could also substantially improve the amorpha-
4,11-diene titer. As sterols fulfill several essential functions
inside the cell, insufficient flux towards ergosterol and other
sterols caused by restricting ERG9 expression was reported
to cause deleterious effect on cell growth [6]. In this case,
the amount and the timing of adding repressors such as
copper sulfate and methionine to the broth during different
growth phases was systematically investigated to avoid
growth inhibition and to achieve the optimal product
titer. In contrast, our dynamic control device harnesses
ergosterol-responsive promoters to adjust ERG9 expression
according to the cell’s need of ergosterols; the sterol level
can be always maintained at an appropriate level for
Figure 3 Growth profile (A) and amorpha-4,11-diene production (B) in engineered strains. Strains M4-D1 ~ D4 with ERG9 under the control
of different ergosterol-responsive promoters were transformed with plasmid pRS415ADS for producing amorpha-4,11-diene. Here, strain M4-D1 ~ D4
are derived from strain M4-2nd with ERG9 under the control of PERG1, PERG11, PERG2 and PERG3, respectively. Strain M4-2nd with plasmid pRS415ADS was
used as control. Strains were cultivated in 250 mL flasks supplemented with 25 mL SC-LEU media. The amorpha-4,11-diene production in engineered
strains was measured using GC-FID after 48 h and 96 h of cultivation. Values represented the average and standard deviation of three independent
experiments.
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Figure 4 qRT-PCR analysis of ERG9 expression in the engineered strains. Five cultures of each strain, M4-2nd, M4-D1, M4-D2, M4-D3 and
M4-D4 were inoculated in SC media at initial OD600 of 0.05 and harvested during early-log phase for qRT-PCR analysis. All strains harboring
plasmid pRS415ADS were subjected to qRT-PCR analysis to determine ERG9 expression levels in engineered strains. The results are presented
as the relative abundances of ERG9 in each strain with respect to that of ACT1. Values represented the average and standard deviation of three
independent experiments.
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ure 1). Once the cell senses the excess of ergosterol, ERG9
expression under the control of these ergosterol-responsive
promoters will be tuned down, which will result in redirec-
tion of the metabolic flux towards non-native isopren-
oid production. Another benefit of ergosterol-
regulated system for dynamic control of ERG9 expression
is that it also eliminates the requirement of adding repres-
sors such as copper sulfate or methionine, which will sig-
nificantly simplify the fermentation process, as well as
reduce production costs.
In the future, promoter engineering using error-prone
PCR can be further explored to improve the sensitivity
and dynamic range of these ergosterol-responsive
promoters, and to achieve even tighter control of
gene expression. Alternatively, hybrid promoter systems
may also be developed by fusion of ergosterol-responsive
elements with other well-studied promoters. Furthermore,
degradation signal through N-End rule [26,27] may
be further used to modulate the enzyme turnover
rate for a more robust and accurate dynamic control
device.
Conclusions
In summary, a dynamic control device using side-
product regulated system offers an alternative strategy
to conventional approaches, such as gene deletion or
CTR3/MET3 repressible promoters, for restrictingmetabolic flux towards side-product biosynthesis. The
methodology described here would serve well as a
generalized technique for engineering additional metabolic
pathways.
Methods
Strains, plasmids and reagents
Escherichia coli strain DH5α was used for general plas-
mid constructions and the strain was cultivated at 37°C
in Luria-Bertani medium with 100 μg/mL ampicillin.
Previously engineered S. cerevisiae strain M4-2nd with
high mevalonate pathway activity was used as the paren-
tal strain for all yeast strain constructions. This strain
was cultured in rich YPD medium. Engineered strains
with different auxotrophic selection markers were grown
in synthetic complete (SC) medium with leucine or ura-
cil dropout where appropriate. For induction of genes
under the control of galactose inducible promoters, S.
cerevisiae strains were grown in 1.8% galactose plus 0.2%
glucose. Plasmid pSH68 and pUG72 were obtained from
EUROSCRAFF. Plasmid pRS425ADS with the codon op-
timized amorpha-4,11-diene synthase (ADS) gene from
the plant Artemisia annua [9] was kindly provided by
Prof. Jay Keasling from University of California,
Berkeley. Restriction enzymes, Taq polymerase, alkaline
phosphatase (CIP) and T4 ligase were purchased from
New England Biolabs (Beverly, MA). iProof HF polymer-
ase and iScriptTM Reverse Transcription Supermix were
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kit, PCR purification kit, Plasmid purification kit and
RNeasy Mini Kit were purchased from QIAGEN (Hil-
den, Germany). FastStart Essential DNA Green Master
Mix was purchased from Roche (Singapore, SG). All of
the chemicals used in this study were purchased from
Sigma-Aldrich (St. Louis, MO).
Plasmid construction and yeast transformation
Oligonucleotides used for plasmid construction are listed
in Table 3. To create the genome integration cassette, a
series of plasmids was constructed as follows. Firstly,




































R_ERG9_q TTCTGCAAAACTTCAGCTTCAAamplified from plasmid pUG72 using primer pair
F_URA3_HindIII/R_URA3_BE. The PCR product with
size around 1.4 kb was purified, digested with HindIII/
EcoRI and inserted into pUC18 cut with the same enzyme
pair, to yield pURA3-Blank. Next, the 801 bp promoter re-
gion of ERG1 was amplified from genomic DNA of S. cer-
evisiae BY4742 using primer pair F_ERG1p_BamHI/
R_ERG1p_EcoRI. The PCR product was cut with BamHI/
EcoRI, and inserted into pURA3-Blank cut with BamHI/
EcoRI, to yield pURA3-ERG1p. Similarly, the 1000 bp pro-
moter region of ERG11, the 807 bp promoter region of
ERG2, and the 802 bp promoter region of ERG3 were
PCR amplified from genomic DNA of S. cerevisiae, cut
with BamHI/EcoRI, and inserted into pURA3-Blank cut
with BamHI/EcoRI, to yield plasmid pURA3-ERG11p,
pURA3-ERG2p and pURA3-ERG3p, respectively (Table 2).
To this end, these plasmids served as template for the
amplification of genome integration cassette using primer
pair F_ERG9p_Int/R_ERG9p_Int.
For generating the mutant strains with ERG9 under
the control of different ergosterol-responsive promoters,
electroporation was carried out as follows. Fresh overnight
culture of strain M4-2nd was inoculated into 50 mL YPD
medium to an initial OD600 0.3. Yeast cells were harvested
by centrifugation at 4°C, 1500 g for 5 min after 4–5 h
when OD600 reached 1.3. The cell pellet was washed twice
with 50 mL ice-cold Milli-Q water, followed by centrifuga-
tion to collect the cells. Next, the cells were washed with
4 mL ice-cold 1 M sorbitol, pelleted by centrifuge and
finally re-suspended in ice-cold sorbitol to a final volume
of 400 μL. Subsequently, 50 μL of yeast cells together with
approximately 2 μg of genome integration cassette
were electroporated in a 0.2 cm cuvette at 1.6 kV. After
electroporation, cells were immediately mixed with 2 mL
pre-warmed YPD medium and shaken for 90 min on a
rotary shaker to recover the cells. Cells were spotted on
SC-URA plates and incubated at 30°C for 3–4 days until
colonies appeared. Strains with successful replacement of
native ERG9 promoter were verified by diagnostic PCR.
Since previous investigation showed that low copy
expression of ADS gene resulted in higher amorpha-
4,11-diene titers [28], centromeric plasmid based expres-
sion of ADS gene was created as follows. Briefly, ADS gene
was amplified from pRS425ADS, cut with BamHI/XhoI
and inserted into pSH68 cut with the same enzyme pair, to
yield pRS415ADS. For the transformation of pRS415ADS
into engineered strains, the standard lithium acetate
method was used and the transformed cells were spotted
on SC-LEU plates for selection.
RNA extraction and quantitative real-time PCR
Yeast cells were harvested at early-log phase and total
amount of 1 × 107 cells was used for the total RNA extrac-
tion using the RNeasy Mini Kit (QIAGEN, Germany).
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using iScriptTM Reverse Transcription Supermix from
Biorad (Hercules, CA).
The gene-specific primers for EGR9, ERG1, ERG11, ERG2,
ERG3 and ACT1 were designed using the ProbeFinder
(https://lifescience.roche.com), and oligonucleotides used
for qRT-PCR experiment were listed in Table 3. Quantita-
tive PCR analysis was carried out using LightCycler 96
real-time machine with FastStart Essential DNA Green
Master Mix (Roche) according to the manufacturer’s in-
structions. Each 20 μL reaction contained 50 ng of total
cDNA, 10 μL FastStart Essential DNA Green Master Mix,
0.5 μM of each primer. Thermal cycling conditions were
set as follows: pre-incubation, 1 cycle of 95°C for 10 min;
amplification, 45 cycles of 95°C for 10 s, 57°C for 10 s
and 72°C for 10 s. ACT1 was chosen as a reference
housekeeping gene and the results were presented as
ratios of gene expression between the ERG9, ERG1,
ERG11, ERG2, ERG3 and the reference gene, ACT1
[29].
Amorpha-4,11-diene production in engineered yeast
To investigate the effect of ergosterol-responsive pro-
moters on restricting ERG9 expression in the engineered
strains, both the growth profile and amorpha-4,11-diene
production profile were investigated. Strains harboring
pRS415ADS were inoculated into SC-LEU medium. The
next day, 250 mL flasks containing 25 mL SC-LEU
medium (1.8% galactose + 0.2% glucose) were inoculated
with fresh cell cultures to an initial OD600 of 0.05. All
flasks were immediately supplemented with 20%
(vol/vol) dodecane after seeding, to perform two phase
fermentation and harvest amorpha-4,11-diene. The
growth profile was continuously monitored for 4 days.
The amorpha-4,11-diene levels were measured after 48 h
or 96 h cultivation. Every time, 100 μL of cell culture was
taken for measuring OD600 by microplate reader (Synergy
H1, BioTek, USA), and 10 μL dodecane layer was sampled
and diluted in 990 μL ethyl acetate for the quantitation of
amorpha-4,11-diene levels using gas chromatography-
flame ionization detector (GC-FID). For GC-FID analysis,
1 μL of diluted sample was injected into Shimadzu
QP2010Ultra system equipped with a DB-5 column
(Agilent Technologies, USA). Hydrogen was used as a
carrier gas at a flow rate of 1.0 mL/min. The oven
temperature was first kept constant at 80°C for 2 min, and
then ramped to 190°C at a rate of 5°C/min, and finally
increased to 300°C by 20°C/min. For the quantitation of
amorpha-4,11-diene levels, caryophyllene was used for
plotting the standard curve and the results shown in the
present study are presented as caryophyllene equivalents.
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